Patents by Inventor Pritom Shah

Pritom Shah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11453666
    Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: September 27, 2022
    Assignee: Cancer Research Technology Limited
    Inventors: Martin Lee Stockley, Ellen Catherine Macdonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
  • Publication number: 20200283435
    Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 10, 2020
    Inventors: Martin Lee Stockley, Ellen Catherine Macdonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
  • Patent number: 10654846
    Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: May 19, 2020
    Assignee: Cancer Research Technology Limited
    Inventors: Martin Lee Stockley, Ellen Catherine MacDonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
  • Patent number: 10428061
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 1, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
  • Publication number: 20190062324
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 28, 2019
    Inventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
  • Patent number: 10138230
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: November 27, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Francesca Blum, James Lindsay Carr, Pritom Shah, Maria Del Mar Jimenez Quesada, Irene Farre Gutierrez
  • Publication number: 20180022742
    Abstract: The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 25, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Francesca BLUM, James Lindsay CARR, Pritom SHAH, Maria DEL MAR JIMENEZ QUESADA, Irene FARRE GUTIERREZ
  • Publication number: 20180016274
    Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Application
    Filed: February 4, 2016
    Publication date: January 18, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Martin Lee STOCKLEY, Ellen Catherine MACDONALD, Pritom SHAH, Allan JORDAN, James HITCHIN, Niall HAMILTON
  • Publication number: 20090274655
    Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.
    Type: Application
    Filed: November 15, 2007
    Publication date: November 5, 2009
    Inventors: Richard Martin Grimes, Charles David Hartley, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
  • Publication number: 20090136448
    Abstract: Anti-viral agents of compounds of Formula (I): wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.
    Type: Application
    Filed: December 20, 2006
    Publication date: May 28, 2009
    Inventors: John Andrew Corfield, Richard Martin Grimes, David Harrison, Charles David Hartley, Peter David Howes, Joelle Le, Malcolm Lees Meeson, Jacqueline Elizabeth Mordaunt, Pritom Shah, Martin John Slater, Gemma Victoria White
  • Patent number: 7304087
    Abstract: Anti-viral agents of Formula (I) wherein: A represents hydroxy; D represents aryl or heteroaryl; E represents hydrogen, C1-6alkyl, aryl, heteroaryl or heterocyclyl; G represents hydrogen or optionally substituted C1-6alkyl; J represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl; processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: December 4, 2007
    Assignee: Glaxo Group Limited
    Inventors: David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Pritom Shah, Martin John Slater
  • Patent number: 7259163
    Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: August 21, 2007
    Assignee: Glaxo Group Limited
    Inventors: Gianpaolo Bravi, Rossella Guidetti, David Haigh, Charles David Hartley, Peter David Howes, Deborah Lynette Jackson, Victoria Lucy Helen Lovegrove, Pritom Shah, Martin John Slater, Katrina Jane Wareing
  • Publication number: 20070167507
    Abstract: Novel antiviral compounds of Formula (I): wherein: A represents hydroxy; R1 represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, C1-6alkyl or —C5-9cycloalkyl, each of which may be optionally substituted; R2 represents substituted phenyl, or —(CH2)nC5-7cycloalkyl optionally substituted on the cycloalkyl; R3 represents heterocyclyl or heteroaryl; optionally substituted phenyl or optionally substituted —C1-6alkyl; R4 represents hydrogen; and salts, solvates and esters thereof processes for their preparation, pharmaceutical compositions comprising them, and methods of using them in HCV treatment are provided.
    Type: Application
    Filed: March 22, 2005
    Publication date: July 19, 2007
    Applicants: GLAXO GROUP LIMITED, SMITHKLINE BEECHAM CORPORATION
    Inventors: Gianpaolo Bravi, John Corfield, Richard Grimes, Rossella Guidetti, Victoria Lucy Lovegrove, Jacqueline Mordaunt, Pritom Shah, Martin Slater
  • Publication number: 20050043545
    Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 5-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.
    Type: Application
    Filed: October 30, 2002
    Publication date: February 24, 2005
    Inventors: Gianpalol Bravi, Helene Goodland, David Haigh, Charles Hartley, Victoria Lovegrove, Pritom Shah, Martin Slater
  • Publication number: 20050043390
    Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6-alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.
    Type: Application
    Filed: October 30, 2002
    Publication date: February 24, 2005
    Inventors: Gianpaolo Bravi, Rossella Guidetti, David Haigh, Charles Hartley, Peter Howes, Deborah Jackson, Victoria Lovegrove, Pritom Shah, Martin Slater, Katrina Wareing
  • Publication number: 20050009873
    Abstract: Novel anti-viral agents of Formula (I) wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; D represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; E represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts and solvates thereof, processes for their preparation and methods of using them in HCV treatment are provided.
    Type: Application
    Filed: October 30, 2002
    Publication date: January 13, 2005
    Inventors: Gianpaolo Bravi, Peter Howes, Victoria Lovegrove, Pritom Shah, Martin Slater
  • Patent number: 6215002
    Abstract: There are described according to the invention, processes for making compounds of formula (XXVIII)3 (relative stereochemistry indicated), wherein P2 is as defined in the specification.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: April 10, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Inglis, Martin Redpath Johnson, Simon John Fawcett MacDonald, Pritom Shah, Robin Andrew Smith
  • Patent number: 6177425
    Abstract: According to the invention there are provided Hexahydro-Pyrrolo[3,4-b]pyrrol-2-one compounds of formula (1), (relative stereochemistry indicated), wherein R1, R2 and R3 are as defined in the specification. Compounds of formula (1) are useful inter alia in the treatment or chronic bronchitis.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: January 23, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Adam Inglis, Martin Redpath Johnson, Simon John Fawcett MacDonald, Pritom Shah
  • Patent number: 5994344
    Abstract: There are described according to the invention compounds of formula (I) (relative stereochemistry indicated), wherein R.sub.1, R.sub.2, R.sub.3 and X are as defined in the specification, together with processes for preparing them, compositions containing them and their use as pharmaceuticals. Compounds of formula (I) are indicated inter alia for the treatment of chronic bronchitis.
    Type: Grant
    Filed: September 25, 1998
    Date of Patent: November 30, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael Dennis Dowle, Harry Finch, Lee Andrew Harrison, Graham George Inglis, Martin Redpath Johnson, Simon John Fawcett Macdonald, Pritom Shah, Robin Andrew Smith
  • Patent number: 5641775
    Abstract: The invention relates to 3-phenylureido-1,5-benzodiazepine-diones of formula (I) ##STR1## and pharmaceutically acceptable salts and solvates thereof, and to their use as gastrin/CCK-B antagonists.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: June 24, 1997
    Assignee: Glaxo SpA
    Inventors: Harry Finch, David Gordon Trist, Aldo Feriani, Giorgio Tarzia, Pritom Shah